LRRK2

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Monday, March 18, 2024
Employment, Development, ARVN, PROTAC, Pfizer, Oncology, Partnership, Novartis, Executive, Patient, Knowledge, National Cancer Institute, Bristol Myers Squibb, BMS, Neuroscience, Columbia University, LRRK2, Pharmaceutical industry

Effective today, Dr. Berkowitz will lead the ongoing clinical development of Arvinas’ PROTAC® protein degrader programs in oncology and neuroscience.

Key Points: 
  • Effective today, Dr. Berkowitz will lead the ongoing clinical development of Arvinas’ PROTAC® protein degrader programs in oncology and neuroscience.
  • “We are thrilled to have Dr. Berkowitz join Arvinas as we continue advancing multiple programs with the goal of improving the lives of patients with serious diseases,” said John Houston, Ph.D., Chairperson, President and Chief Executive Officer at Arvinas.
  • Dr. Berkowitz joins Arvinas from Bristol-Myers Squibb (BMS), where he was Senior Vice President, Development Unit Head, Hematology.
  • The option and restricted stock units were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas’ stock incentive plan.

Brenig Therapeutics Presented New Data for the Best-in-Class LRRK2 Inhibitor Targeting Parkinson's Disease at the ACS Spring 2024 Conference

Retrieved on: 
Monday, March 18, 2024
IPD, Brain, Conference, Disease, PD, CSF, Lung, OrbiMed, Traffic barrier, Parkinson's disease, LRRK2, Therapy, Safety, ACS, Kidney, Pharmaceutical industry

DOVER, Del., March 18, 2024 /PRNewswire/ -- Brenig Therapeutics, a portfolio company of Torrey Pines Investments, OrbiMed Advisors, and BioGeneration Ventures, focusing on treatment of neurodegenerative diseases, presented new safety data on its LRRK2 inhibitor drug candidate at the ACS Spring 2024 Conference at the New Orleans Ernest N. Morial Convention Center, on March 17th, 2024.

Key Points: 
  • DOVER, Del., March 18, 2024 /PRNewswire/ -- Brenig Therapeutics, a portfolio company of Torrey Pines Investments, OrbiMed Advisors, and BioGeneration Ventures, focusing on treatment of neurodegenerative diseases, presented new safety data on its LRRK2 inhibitor drug candidate at the ACS Spring 2024 Conference at the New Orleans Ernest N. Morial Convention Center, on March 17th, 2024.
  • Brenig's innovative approach to the rationally designed LRRK2 inhibitor (BT-0267) marks a significant stride in the company's mission to combat neurodegenerative diseases.
  • LRRK2, a key protein implicated in Parkinson's disease (PD), has been a challenging therapeutic target.
  • Current data highlights the superior safety profile of LRRK2 Inhibitor BT-0267 with an exceptional CSF to plasma ratio, in vivo efficacy of BT-0267 in brain and no visible lung and kidney morphological changes compared to other LRRK2 inhibitor candidates.

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, February 27, 2024
MPS II, Hearing, ARIA, Antibody, LRRK2, PTV, IDS, Transferrin receptor, MAPT, Traffic barrier, ALS, Hunting, Dermatan sulfate, Therapy, BBB, SAN, Total, Amyloid-related imaging abnormalities, Alpha-synuclein, COMPASS, ETV, Hunter syndrome, Neurodegenerative disease, Conference, MPS, Safety, Biomarker, OTV, LUMA, AFL, SNCA, Amyloid beta, CSF, PIPE, Glycogen storage disease, Research, ATV, FDA, Food, Risk, Sanofi, UC, CD98, Patient, Cognition, Oligonucleotide, Science, Alfa, Pharmaceutical industry

Enrollment continues in the global Phase 2/3 COMPASS study and is expected to be completed in 2024.

Key Points: 
  • Enrollment continues in the global Phase 2/3 COMPASS study and is expected to be completed in 2024.
  • Sanofi intends to present the detailed efficacy and safety results of the ALS Phase 2 HIMALAYA study at a future scientific forum.
  • There was no collaboration revenue for the quarter ended December 31, 2023, compared to $10.3 million for the quarter ended December 31, 2022.
  • Further, for the quarter ended December 31, 2023, there was also a decrease in other unallocated research and development expenses as a result of reduced facility costs.

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 27, 2024
CDK4, ESPP, Research, BCL6, Sale, Exercise, LRRK2, ARVN, CDK7, ATM, HER2, Genentech, European Medicines Agency, Congress, Development, Breast cancer, Pfizer, CBR, ESMO, Everolimus, Greyhawk, ESR1, Oncology, Enrollment, Investment, Insurance, Prostate cancer, PFS, Food, Ribociclib, Bayer, Administration, Patient, Neutropenia, Pharmaceutical industry

NEW HAVEN, Conn., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Median PFS of 11.1 and 11.0 months in patients with ESR1 wild-type and ESR1 mutant tumors, respectively.
  • Announced the appointment of Randy Teel, Ph.D., Arvinas’ current senior vice president of corporate and business development, to the role of interim chief financial officer and treasurer.
  • The Arvinas Board of Directors has launched a formal search process to identify Mr. Cassidy’s permanent replacement.
  • Revenues: Revenue was $78.5 million and $(43.1) million for the year and quarter ended December 31, 2023 as compared with $131.4 million and $38.0 million for the year and quarter ended December 31, 2022.

Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease

Retrieved on: 
Tuesday, February 20, 2024
Proteolysis, Traffic barrier, Senior, DSM-IV codes, Palsy, LRRK2, ARVN, Safety, Event, Biomarker, Pharmacokinetics, Patient, CHDR, PROTAC, Pharmaceutical industry

NEW HAVEN, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the first subject was dosed in its Phase 1 clinical trial of ARV-102, the Company’s first oral PROTAC® (PROteolysis-TArgeting Chimera) protein degrader in development to treat neurodegenerative diseases. In preclinical studies, ARV-102 has been shown to cross the blood-brain barrier and degrade leucine-rich repeat kinase 2 (LRRK2), which is a large multidomain scaffolding kinase. Increased activity and expressions of LRRK2 is genetically involved in the pathogenesis of neurological diseases including Parkinson’s disease and progressive supranuclear palsy.

Key Points: 
  • In preclinical studies, ARV-102 has been shown to cross the blood-brain barrier and degrade leucine-rich repeat kinase 2 (LRRK2), which is a large multidomain scaffolding kinase.
  • Increased activity and expressions of LRRK2 is genetically involved in the pathogenesis of neurological diseases including Parkinson’s disease and progressive supranuclear palsy.
  • In non-human primates, orally administered ARV-102 has been shown to reach deep-brain regions and degrade LRRK2 by nearly 90%.
  • The Phase 1 clinical trial of ARV-102 is enrolling healthy volunteers at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands.

Halia Therapeutics Announces Collaboration with Canary Speech to Leverage its Cutting Edge AI- Driven Speech Technology to Advance the Clinical Development of Novel Therapeutics Targeting Neuroinflammation

Retrieved on: 
Tuesday, February 6, 2024
Intelligence, AI, Patient, LEHI, Alzheimer's disease, Leucine, Disease, Therapy, Drug development, LRRK2, Algorithm, Health, Iñaki, Medical device

LEHI, Utah, Feb. 6, 2024 /PRNewswire/ -- Halia Therapeutics, a pharmaceutical company at the forefront of developing neuroinflammation-targeting drugs, and Canary Speech, a leader in artificial intelligence vocal biomarker technology, today announced a collaboration to revolutionize the way Alzheimer's disease can be monitored and treated.

Key Points: 
  • This collaboration leverages Canary Speech's state-of-the-art AI vocal biomarker platform which utilizes advanced AI algorithms to analyze subtle changes in voice patterns and monitor cognitive function changes in Alzheimer's patients.
  • This non-invasive, efficient method offers a revolutionary approach to tracking the progression of Alzheimer's disease and the effectiveness of treatments.
  • "Canary AI-driven Speech technology will provide invaluable data to help us tailor our therapies more effectively and improve outcomes for patients with this debilitating neurodegenerative disease".
  • "We are thrilled to be combining our pioneering AI technology with Halia's' expertise in drug development targeting neuro-inflammation," said Henry O'Connell, CEO and Co-founder of Canary Speech.

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Retrieved on: 
Monday, January 8, 2024
CSF, Lysosomal storage disease, Cerebrospinal fluid, Risk, Sanfilippo syndrome, Amyloid, BBB, UC, Sanfilippo, Manuscript, ETV, ALS, OTV, SNCA, IDS, Asos, Conference, Cognition, RIPK1, Fluid mechanics, Neuroinflammation, Premedication, Glycogen storage disease, Amyloid beta, SGSH, Therapy, COMPASS, Traffic barrier, Hunting, N-sulfoglucosamine sulfohydrolase, Hunter syndrome, ISR, NewCo, Amyloid-related imaging abnormalities, Inflammation, CNS, Neurodegenerative disease, Takeda, Biomarker, Alpha-synuclein, K2, Biology, DSM-IV codes, LUMA, Brain, MPS, Investigational New Drug, PTV, ARIA, Nerve, AFL, Pathology, MPS II, Interim, BioRxiv, Plaque, MAPT, LRRK2, Elevator mechanic

The global Phase 2/3 COMPASS study continues to recruit up to 54 participants with neuronopathic and non-neuronopathic MPS II.

Key Points: 
  • The global Phase 2/3 COMPASS study continues to recruit up to 54 participants with neuronopathic and non-neuronopathic MPS II.
  • Upon completion of the ongoing Phase 1/2 study, and together with data from COMPASS, this combined data package is intended to support registration.
  • Increased RIPK1 activity in the CNS is hypothesized to drive neuroinflammation and cell necroptosis and to contribute to neurodegeneration.
  • Denali will maintain ownership of and continue to advance its current portfolio of clinical stage small molecule programs.

Brenig Therapeutics Unveils Superior Safety Profile of LRRK2 Inhibitor BT-0267 with Exceptional CSF/Plasma Ratio at Future of Parkinson's Disease Conference

Retrieved on: 
Monday, December 4, 2023
Parkinson's disease, Lung, Brain, SAN, Therapy, CSF, Kidney, OrbiMed, Conference, LRRK2, Fiat 500X, Cerebrospinal fluid, Traffic barrier, Pharmaceutical industry

The results were unveiled at the prestigious Future of Parkinson's Disease Conference.

Key Points: 
  • The results were unveiled at the prestigious Future of Parkinson's Disease Conference.
  • LRRK2, recognized as a crucial drug target in Parkinson's disease, plays a major role in the pathogenesis of the condition.
  • Inhibiting LRRK2 activity has emerged as a promising disease-modifying therapeutic strategy, and several drug candidates have achieved clinical status.
  • The BT-0267 candidate has an efficient blood-brain barrier penetration while minimized peripheral exposure as well as has a superior overall safety profile.

Smart or AI In-Vitro Diagnostics Market to Record an Exponential CAGR by 2031 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Wednesday, November 29, 2023
Brain, Research, POC, Conditional sentence, Prevalence, Parkinson's disease, Pathology, Incidence, CDX, Urbanization, Cancer, CE, Infection, COVID-19, Mylab Discovery Solutions, RT, Diagnosis, LRRK2, Growth, NGS, IVD, Hospital, AI, Diabetes, IVDR, Marie Cassidy, Qiagen, Medical device, Pharmaceutical industry

The primary driver of market development is the rising incidence of chronic diseases like cancer, diabetes, and others in the nation.

Key Points: 
  • The primary driver of market development is the rising incidence of chronic diseases like cancer, diabetes, and others in the nation.
  • This will increase the need for in-vitro diagnostics, which is expected to propel market growth throughout the forecast period.
  • Additionally, cutting-edge medical technology advancements, including biosensors, lab-on-a-chip, wearables, and POC diagnostics, are progressively playing a significant role in healthcare.
  • The North America Smart or AI In-Vitro Diagnostics market is expected to record a noteworthy market share in revenue and grow at a high CAGR shortly.

Smart or AI In-Vitro Diagnostics Market to Record an Exponential CAGR by 2031 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Wednesday, November 29, 2023
Brain, Research, POC, Conditional sentence, Prevalence, Parkinson's disease, Pathology, Incidence, CDX, Urbanization, Cancer, CE, Infection, COVID-19, Mylab Discovery Solutions, RT, Diagnosis, LRRK2, Growth, NGS, IVD, Hospital, AI, Diabetes, IVDR, Marie Cassidy, Qiagen, Medical device, Pharmaceutical industry

The primary driver of market development is the rising incidence of chronic diseases like cancer, diabetes, and others in the nation.

Key Points: 
  • The primary driver of market development is the rising incidence of chronic diseases like cancer, diabetes, and others in the nation.
  • This will increase the need for in-vitro diagnostics, which is expected to propel market growth throughout the forecast period.
  • Additionally, cutting-edge medical technology advancements, including biosensors, lab-on-a-chip, wearables, and POC diagnostics, are progressively playing a significant role in healthcare.
  • The North America Smart or AI In-Vitro Diagnostics market is expected to record a noteworthy market share in revenue and grow at a high CAGR shortly.